Prosecution Insights
Last updated: April 19, 2026
Application No. 18/462,918

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Final Rejection §103§DP
Filed
Sep 07, 2023
Examiner
NOLAN, JASON MICHAEL
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
AbbVie Inc.
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
2y 11m
To Grant
37%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allow Rate
235 granted / 355 resolved
+6.2% vs TC avg
Minimal -29% lift
Without
With
+-29.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
45 currently pending
Career history
400
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
22.2%
-17.8% vs TC avg
§102
22.8%
-17.2% vs TC avg
§112
32.2%
-7.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 355 resolved cases

Office Action

§103 §DP
DETAILED ACTION A non-final Office action was mailed 19 March 2025 (“Office Action”). Applicant’s reply was received 19 September 2025. Status of the Claims The listing of claims filed 19 September 2025 has been considered. Claims 1, 7, 13, 17, 18, 20–22, 25, 45, 48, 50, 62, 64–68, 87, 88, and 91 are pending. Claims 1, 45, 48, 50, 62, 64 – 68, 88, and 91 are amended. Claims 2–6, 8–12, 14–16, 19, 23, 24, 26–44, 46, 47, 49, 51–61, 63, 69–86, 89, and 90 are canceled. Claims 25, 68, 87, 88, and 91 are withdrawn. Information Disclosure Statement The information disclosure statement (IDS) submitted on 19 September 2025 is acknowledged and has been considered. Status of Rejections and Objections Unless repeated herein, any objection or rejection set forth in the Office Action is withdrawn. In particular, the claim amendments overcome the rejection under 35 U.S.C. § 102 and several double patenting rejections. Applicant’s argument with respect to the rejection under 35 U.S.C. § 103 is persuasive and that rejection is withdrawn. The text providing the basis for non-statutory double patenting rejections not included in this action can be found in the Office Action. Scope of Search and Examination Applicant has overcome the prior art rejections of record, so the search was further extended to more non-elected species. Claim 1 is free of the prior art. The restriction of claim 25 based on the election of species is withdrawn and claim 25 is rejoined. A double patenting rejection of claim 66 is maintained herein. Claims 68, 87, 88, and 91 remain withdrawn. Double Patenting Claim 66 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 59 of copending Application No. 18/463,183 (“the ’183 application” or “reference claim”). Although the conflicting claims are not identical, they are not patentably distinct from each other because at least one compound is claimed in claim 66 and the reference claim: PNG media_image1.png 141 189 media_image1.png Greyscale The conflicting claims have not been unnecessarily searched and may share other compounds. Applicant is encouraged to review conflicting claims for additional overlap. Due to the overlap in the claimed subject matter, an infringer of a patent granted based on the claim of the instant application or the reference claim may also be an infringer of the other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not been patented. Allowable Subject Matter Claims 1, 7, 13, 17, 18, 20–22, 25, 45, 48, 50, 62, 64, 65, and 67 are allowed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 C.F.R. § 1.17(a)) pursuant to 37 C.F.R. § 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Communication Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jason Nolan at (571) 272-2480. The examiner can normally be reached Monday through Friday between 9:00–5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to submit an Automated Interview Request: http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JASON M. NOLAN/Patent Examiner, Art Unit 1623 /ADAM C MILLIGAN/Supervisory Patent Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Sep 07, 2023
Application Filed
Mar 04, 2025
Non-Final Rejection — §103, §DP
Sep 19, 2025
Response Filed
Oct 15, 2025
Final Rejection — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12583824
6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
2y 5m to grant Granted Mar 24, 2026
Patent 12570661
Isoform-Specific Aldehyde Dehydrogenase Inhibitors
2y 5m to grant Granted Mar 10, 2026
Patent 12565483
OXOPYRROLIDINE UREA FPR2 AGONISTS
2y 5m to grant Granted Mar 03, 2026
Patent 12553092
ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY
2y 5m to grant Granted Feb 17, 2026
Patent 12522566
2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER
2y 5m to grant Granted Jan 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
37%
With Interview (-29.1%)
2y 11m
Median Time to Grant
Moderate
PTA Risk
Based on 355 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month